Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Single Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)

    Cancer Categories
    • Lung
    Karmanos Trial ID
    • 2023-038
    NCT ID
    • NCT05860296
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator

    Objective:

    Primary Objectives:

    • Phase 1b: To determine the safety and RP2D of SLC-391 in combination with
      pembrolizumab.
    • Phase 2: To evaluate the antitumor activity of SLC-391 (ORR) in combination with pembrolizumab, as assessed by the Investigators using RECIST version 1.1, separately for each cohort 1 and 2.

    Secondary Objectives:

    • Phase 1b and Phase 2:
      • To further evaluate the safety of SLC-391 in combination with pembrolizumab.
      • To evaluate the PK of SLC-391 when administered in combination with
        pembrolizumab.
    • Phase 1b and Phase 2: To assess additional measures of the antitumor activity of SLC-391
      in combination with pembrolizumab, as assessed by Investigators, including:
      • ORR by immune-RECIST (iRECIST)
      • Disease control rate (DCR) by RECIST 1.1 and iRECIST
      • Time-to-response (TTR) by RECIST 1.1 and iRECIST
      • DoR by RECIST 1.1 and iRECIST
      • PFS by RECIST 1.1 and iRECIST
      • Time-to-progression (TTP) by RECIST 1.1 and iRECIST
      • OS.
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266